XORTX Therapeutics (TSXV:XRTX) Receivables Turnover : 0.00 (As of Sep. 2024)

View and export this data going back to 2015. Start your Free Trial

What is XORTX Therapeutics Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. XORTX Therapeutics's Revenue for the three months ended in Sep. 2024 was C$0.00 Mil. XORTX Therapeutics's average Accounts Receivable for the three months ended in Sep. 2024 was C$0.03 Mil.

XORTX Therapeutics Receivables Turnover Historical Data

The historical data trend for XORTX Therapeutics's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XORTX Therapeutics Receivables Turnover Chart

XORTX Therapeutics Annual Data

Trend

Feb15

Feb16

Feb17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Receivables Turnover

Get a 7-Day Free Trial

XORTX Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Receivables Turnover	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of XORTX Therapeutics's Receivables Turnover

For the Biotechnology subindustry, XORTX Therapeutics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

XORTX Therapeutics's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XORTX Therapeutics's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where XORTX Therapeutics's Receivables Turnover falls into.

XORTX Therapeutics Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

XORTX Therapeutics's Receivables Turnover for the fiscal year that ended in Dec. 2023 is calculated as

	Receivables Turnover (A: Dec. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Dec. 2023 )	/ (	(Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )
=	0	/ (	(0.111	+	0.082)	/	2 )
=	0	/	0.0965
=	N/A

XORTX Therapeutics's Receivables Turnover for the quarter that ended in Sep. 2024 is calculated as

	Receivables Turnover (Q: Sep. 2024 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Sep. 2024 )	/ (	(Accounts Receivable (Q: Jun. 2024 )	+	Accounts Receivable (Q: Sep. 2024 ))	/	count )
=	0	/ (	(0.032	+	0.018)	/	2 )
=	0	/	0.025
=	N/A

XORTX Therapeutics (TSXV:XRTX) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

XORTX Therapeutics Receivables Turnover Related Terms

Thank you for viewing the detailed overview of XORTX Therapeutics's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

XORTX Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XORTX Therapeutics Inc (TSXV:XRTX) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

XRTX:USA ANUA:Germany

Address

3710 - 33rd Street NW, Calgary, AB, CAN, T2L 2M1

Website

https://www.xortx.com

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.

Executives

Allen Warren Davidoff	Director, Senior Officer
Amar Deep Keshri	Senior Officer
William Bruce Rowlands	Director
James Neville Fairbairn	Senior Officer
Allan William Williams	Director
Paul Joseph Van Damme	Director